Mersana Therapeutics, Inc. (MRSN)
Chart Events
Performance Outlook
| Previous Close | 18.48 |
| Open | 18.20 |
| Bid | 19.42 x 800 |
| Ask | 19.48 x 2200 |
| Day's Range | 17.96 - 19.56 |
| 52 Week Range | 1.32 - 26.64 |
| Volume | 222,315 |
| Avg. Volume | 922,157 |
| Market Cap | 1.323B |
| Beta (5Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings Date | Aug 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.80 |
Fair Value
Related Research
- GlobeNewswire
Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data from its novel Immunosynthen STING-agonist ADC platform at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place virtually from November 9-14, 2020. Details of the poster display are as follows:Poster Title: Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates Abstract Number: 620 E-poster Available: 9 a.m. – 5 p.m. ET, November 11-14, 2020. Location: Virtual Poster HallAbout Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.Contact:Investor & Media Contact Sarah Carmody, 617-844-8577 scarmody@mersana.com
- Business Wire
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced plans to move forward with dosing of STK-001 in children and adolescents in its ongoing Phase 1/2a MONARCH study for Dravet syndrome. Following recent interactions with the U.S. Food and Drug Administration (FDA) related to the partial clinical hold on higher dose levels in the MONARCH study, the FDA will allow the Company to add an additional higher dose level to the single ascending dose (SAD) portion of the study (previously Part A). A total of three dose levels will now be evaluated in this portion of the study: 10 mg, 20 mg and 30 mg. Dosing above 30 mg in this study remains on FDA partial clinical hold.
- Insider Monkey
Hedge Funds Keep Into Mersana Therapeutics, Inc. (MRSN)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
- Simply Wall St.
Why Mersana Therapeutics' (NASDAQ:MRSN) CEO Pay Matters
This article will reflect on the compensation paid to Anna Protopapas who has served as CEO of Mersana Therapeutics...
- GlobeNewswire
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
\- Maintained 34% objective response rate and 79% disease control rate, including two complete responses \- XMT-1536 continues to be generally well-tolerated with no new safety signals \- Data to be presented and discussed during a conference call today at 8 a.m. ETCAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported updated interim safety, tolerability and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, as part of the 2020 European Society of Medical Oncology (ESMO) Virtual Congress. The Company will host a conference call and webcast today at 8:00 a.m. ET, during which investigator Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program from the Sarah Cannon Research Institute at Tennessee Oncology, and members of the Mersana executive team will present and discuss these data.“These data further support the continued development of XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, which has recently been granted FDA Fast Track Designation. We are eager to advance XMT-1536 into registration-enabling studies based on its observed antitumor activity and favorable safety profile in an ovarian cancer population with a very poor prognosis and limited treatment options,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “Additionally, we look forward to presenting more comprehensive and mature results from the ongoing expansion cohort around the end of this year.”This interim analysis focused on the ovarian cancer cohort of the Phase 1 expansion study, including heavily pre-treated patients with platinum-resistant or refractory ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy, and in some cases four lines of prior therapy regardless of platinum status. With a data cutoff of August 18, 2020 these data include 47 patients. These data include additional follow up on the 27 ovarian cancer patients previously presented at the American Society of Clinical Oncology (ASCO) virtual program in May of 2020 as well as 20 new patients who entered the study between May 1, 2020 and August 18, 2020.Key findings include:• Safety profile consistent with previously reported expansion data and no new safety signals observed oThe most frequently reported treatment-related adverse events (TRAEs) were generally Grade 1-2 fatigue, nausea, decreased appetite, vomiting and transient AST elevation without associated changes in bilirubin or cases of Hy’s law. oThere were no reported cases of severe neutropenia, peripheral neuropathy or ocular toxicity. •Continued, significant anti-tumor activity in platinum-resistant and platinum-refractory ovarian cancer and in ovarian cancer previously treated with bevacizumab, PARP inhibitors, or both oOf the 29 patients that were evaluable for response, 2/29 (7%) achieved confirmed complete responses (CRs) and 8/29 (28%) achieved confirmed partial responses (PRs) for an objective response rate (ORR) of 34%. Additionally, 13/29 (45%) patients achieved stable disease (SD); the disease control rate (DCR) was 23/29 (79%). •70% of responses were observed within two cycles and 100% of responses were observed within four cycles. Responses appeared to deepen over time, including responses in patients receiving reduced dose levels. •The majority of responders had prior treatment with bevacizumab, PARP inhibitors, or both. Both patients with confirmed CRs had prior treatment with bevacizumab and PARP inhibitors. •Reduction in tumor volume was observed in the majority of patients achieving a best response of stable disease. •Data continue to support a NaPi2b biomarker-based patient selection strategy based on depth, time on study and quality of response o50% of patients with higher NaPi2b expression are ongoing in the study while only 33% of patients with lower Napi2b expression are ongoing in study. Median duration of response was not yet reached in the 7 patients with ovarian cancer with higher NaPi2b expression. oThe Company expects to define the patient selection strategy based on the total data set from patients treated with XMT-1536. Conference Call Details Mersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET to discuss these data. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5731456. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.Forward-Looking Statements This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Company’s product candidates and new platforms will take longer and/or cost more than planned, and that the identification of new product candidates will take longer than planned, as well as those listed in the Company’s Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (“SEC”), the Company’s Quarterly Report on Form 10-Q filed on May 8, 2020, with the SEC and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Company’s preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Company’s operations and the value of and market for the Company’s common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.Contact:Investor & Media Contact Sarah Carmody 617-844-8577 scarmody@mersana.com
- Investopedia
Top Biotech Stocks for Q4 2020
The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. These products must go through a rigorous, costly, and time-consuming testing process before potentially obtaining approval from the U.
- Simply Wall St.
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress
- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present updated interim data from the ovarian cancer cohort of the ongoing Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. These data will be presented in an on-demand e-poster display at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress and will be available beginning Thursday, September 17, 2020.Details of the e-poster display are as follows:Poster Title: Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase I Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate Abstract Number: 2365 Presentation Number: 836P E-poster Available: Thursday, September 17, 2020 at 9:00 a.m. CEST (3:00 a.m. ET) Mersana will also host a live conference call and webcast featuring study investigator, Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program from the Sarah Cannon Research Institute at Tennessee Oncology on Thursday, September 17, 2020 at 8:00 a.m. ET. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5731456. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.Contact:Investor & Media Contact Sarah Carmody, 617-844-8577 scarmody@mersana.com
- Business Wire
Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET.
- GlobeNewswire
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that management will present at two upcoming investor conferences. Details are as follows: Baird 2020 Virtual Global Healthcare Conference Forum: Fireside Chat Date/Time: Thursday, September 10, 2020, at 10:15 a.m. ETCantor Virtual Global Healthcare Conference 2020 Forum: Presentation Date/Time: Tuesday, September 15, 2020, at 3:20 p.m. ETA live webcast of the presentations will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the presentation.About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.Contact:Investor & Media Contact Sarah Carmody 617-844-8577 scarmody@mersana.com
Analyst Price Targets (5)
Upgrades & Downgrades
| Maintains | Baird: to Outperform | 5/28/2020 | |
| Reiterates | SVB Leerink: to Outperform | 5/27/2020 | |
| Reiterates | H.C. Wainwright: to Buy | 5/27/2020 | |
| Downgrade | JP Morgan: Neutral to Underweight | 3/11/2019 | |
| Downgrade | Leerink Swann: Overweight to Market Perform | 7/20/2018 | |
| Maintains | JP Morgan: Neutral to Neutral | 3/19/2018 |
Company Profile
840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020
http://www.mersana.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 83
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
